Related references
Note: Only part of the references are listed.Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2020)
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Emil H. Schemitsch et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective
Mickael Hiligsmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
Sara Kaveh et al.
CLINICAL RHEUMATOLOGY (2020)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE
Pauline M. Camacho et al.
Endocrine Practice (2020)
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture A Randomized Phase-2 Study
Mohit Bhandari et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
S. R. Cummings et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
Sarah Davis et al.
HEALTH TECHNOLOGY ASSESSMENT (2020)
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Persistence and adherence to parenteral osteoporosis therapies: a systematic review
G. Koller et al.
OSTEOPOROSIS INTERNATIONAL (2020)
A decade of FRAX: how has it changed the management of osteoporosis?
John A. Kanis et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2020)
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
Ruban Dhaliwal et al.
JBMR PLUS (2020)
Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women
Takako Suzuki et al.
MODERN RHEUMATOLOGY (2019)
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
P. D. Miller et al.
BONE (2019)
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Mary L. Bouxsein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
S. Ferrari et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture
Beate Lanske et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2019)
Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
J. -Y. Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
H. Chandler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
Pascale Chavassieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
H. Hagino et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
Richard G. Pearson et al.
PHARMACEUTICS (2019)
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial
John P. Bilezikian et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Benjamin Z. Leder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials
S. Lou et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture
Mickael Hiligsmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Abaloparatide: A new pharmacological option for osteoporosis
Allyson Sleeman et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
Takahiro Mori et al.
JBMR PLUS (2019)
Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
Salvatore Minisola et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2019)
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
N. Doyle et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis
Namki Hong et al.
CLINICAL ENDOCRINOLOGY (2018)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
Magnus Bernhardsson et al.
ACTA ORTHOPAEDICA (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
Michael R. McClung et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis
Smriti Murali Krishna et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption
Aurore Varela et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis
D. L. Mana et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Felicia Cosman et al.
MAYO CLINIC PROCEEDINGS (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)
Jacquelin Jolette et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
Yukio Nakamura et al.
BONE RESEARCH (2017)
Using Osteoporosis Therapies in Combination
Michael R. McClung
CURRENT OSTEOPOROSIS REPORTS (2017)
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS
Stewart G. Albert et al.
ENDOCRINE PRACTICE (2017)
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study
Hideaki Ishibashi et al.
BONE (2017)
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
Carolina A. Moreira et al.
BONE (2017)
Effects of sclerostin antibodies in animal models of osteoporosis
Michael Stuart Ominsky et al.
BONE (2017)
Role and mechanism of action of sclerostin in bone
Jesus Delgado-Calle et al.
BONE (2017)
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Guido Kranenburg et al.
ATHEROSCLEROSIS (2016)
Improvement of cancellous bone microstructure in patients on. teriparatide following alendronate pretreatment
Astrid Fahrleitner-Pammer et al.
BONE (2016)
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
Hila Bahar et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Gary Hattersley et al.
ENDOCRINOLOGY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
J. N. Tsai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Teriparatide and denosumab combination therapy and skeletal metabolism
L. Idolazzi et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
Luc Chouinard et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)
Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats
Gao Feng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study
Joy N. Tsai et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
Dae Hyun Kim et al.
PLOS ONE (2015)
Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
Yanfei L. Ma et al.
BONE (2014)
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats
Marina Stolina et al.
BONE (2014)
Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial
Tetsuo Nakano et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Teriparatide Increases Strength of the Peripheral Skeleton in Premenopausal Women With Idiopathic Osteoporosis: A Pilot HR-pQCT Study
Kyle K. Nishiyama et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Multiple Doses of Sclerostin Antibody Romosozumab in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled Study
Desmond Padhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of PTH on osteocyte function
Teresita Bellido et al.
BONE (2013)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study
Adi Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
S. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2013)
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
Elizabeth B. Andrews et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
P. Hadji et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing and Improves Bone Density and Strength of Nonfractured Bones
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1
Davide Gatti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Present at the beginning: a personal reminiscence on the history of teriparatide
R. Marcus
OSTEOPOROSIS INTERNATIONAL (2011)
Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures
Per Aspenberg et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis
I. Imaz et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
J. J. Stepan et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Retreatment With Teriparatide One Year After the First Teriparatide Course in Patients on Continued Long-Term Alendronate
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Teriparatide Retreatment in Osteoporotic Men and Women
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy
I. Fogelman et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study
Helmut Minne et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
Barbara M. Obermayer-Pietsch et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
S. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Robert L. Jilka
BONE (2007)
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial
C Deal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
R Prince et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
MR McClung et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
PQ Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
JM Kaufman et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
E Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
A Randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
JJ Body et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
